共查询到20条相似文献,搜索用时 17 毫秒
1.
Opinion statement Current treatment for hepatitis C virus infection consists of pegylated interferon and ribavirin. The most important predictors
of response to antiviral therapy for HCV include genotype 2 or 3 infection, baseline viral load less than 2 million copies/mL,
and the absence of cirrhosis. Hepatitis C genotype and viral load should be obtained prior to initiating therapy. Liver biopsy
can be used to stage the liver disease, to provide prognostic information, and to evaluate for coexisting causes of liver
injury. Patients with genotype 1 infection require 48 weeks of therapy and a ribavirin dosage of 1000 to 1200 mg/d to achieve
an optimal response. Patients with genotype 2 or 3 infection require only 24 weeks of treatment and a ribavirin dose of 800
mg/d. Treatment may be discontinued in patients who do not have a 100-fold reduction in hepatitis C virus RNA level from baseline
at week 12 because they are unlikely to achieve a sustained response with further therapy. Patients with cirrhosis and hepatic
decompensation or a small hepatocellular carcinoma should be evaluated for liver transplantation. 相似文献
2.
Opinion statement Infection with hepatitis C virus (HCV) accounts for 40% of cases of chronic liver disease in the United States and is now
the most common indication for liver transplantation. Estimates suggest that 4 million people (1.8%) of the American population
are or have been infected with HCV. Currently, the treatment of choice for patients with chronic HCV infection is recombinant
interferon alfa with ribavirin. Pegylated interferons are a promising new development, and in combination with ribavirin,
they will rapidly become the standard of care. The goals of therapy are to slow disease progression, improve hepatic histology,
reduce infectivity, and reduce the risk of hepatocellular carcinoma. Sustained virologic response, which generally implies
the absence of viremia for 6 months or more following completion of therapy, is increasingly being regarded as a cure, with
evidence of slowing or even regression of fibrosis on follow-up liver biopsy. A number of factors have been shown to be predictive
of a sustained response, including viral genotype other than 1, low serum HCV RNA levels, absence of cirrhosis, younger age,
female gender, and shorter duration of infection. Disease severity as assessed by liver biopsy, comorbidities, and possible
contraindications to therapy should be weighed in the decision to begin treatment. Counseling patients regarding transmission,
natural history, and drug and alcohol abstinence also should be included in management. Close monitoring should be done during
treatment for side effects of interferon, including depression and bone marrow suppression. Hemolytic anemia is the major
side effect of ribavirin. 相似文献
3.
Up to 25% of patients with chronic hepatitis C will have persistently normal serum alanine aminotransferase (ALT) levels.
Some studies report that patients with normal ALT levels are more likely to be female and nondrinkers. Patients with persistently
normal transaminases often have mild disease on liver biopsy with little or no fibrosis, but a small number of patients may
have substantial fibrosis or cirrhosis. Traditionally, clinical trials have excluded patients with normal ALT levels; thus,
treatment data are limited. Treatment with interferon monotherapy has been disappointing. Combination therapy with interferon
and ribavirin is controversial but early clinical results have shown good response rates, and data with pegylated interferons
will soon be available. At the current time, therapy for patients with chronic hepatitis C virus with normal ALT levels should
be based on results from a liver biopsy and preferably in the context of a clinical trial. 相似文献
4.
Treatment of hepatitis C 总被引:3,自引:0,他引:3
Hepatitis C virus is a leading cause of chronic liver disease, with over 170 million people infected worldwide. It is also the leading indication for liver transplantation. Complications from chronic hepatitis C infection include cirrhosis, hepatic decompensation, and hepatocellular carcinoma. As a result, treatment strategies to prevent such complications have been widely researched, although many questions remain unanswered. To date, the standard therapy for chronic hepatitis C infection is the combination of peginterferon and ribavirin. Treatment strategies differ based on factors such as genotype and liver biopsy results. Other strategies must be considered for special groups, such as patients with acute hepatitis C infection, hepatitis C/human immunodeficiency virus (HIV) coinfection, and prior nonresponse to interferon or relapse after its use. The goal of therapy is to achieve a sustained virologic response (ie, no detectable hepatitis C ribonucleic acid 6 months after completion of therapy). The substantial adverse effects associated with both interferon alfa and ribavirin often make it difficult for patients to continue with their therapies. 相似文献
5.
Gross JB 《Current Treatment Options in Gastroenterology》2004,7(6):469-475
Opinion statement The main strategy governing treatment of chronic hepatitis C is the prevention of future liver complications. There is good
evidence that curing hepatitis C infection prevents progression of liver disease and allows histologic regression to occur.
Therefore, the primary goal of medical treatment is to cure the viral infection. Combination therapy with peginterferon alfa
and ribavirin is the current standard of care; there are no other medical therapies currently available. Those who failed
to respond to an earlier version of antiviral therapy should strongly consider treatment with peginterferon/ ribavirin if
possible. Nearly half of patients who start peginterferon/ribavirin are unable to achieve a sustained disappearance of infection.
If there were problems related to dosing or adherence the first time around, it is reasonable to consider retreating with
more aggressive support. Nonresponders to the current therapy who have early-stage liver disease can afford to wait until
new antiviral agents come along in the next 5 to 10 years. However, physicians should encourage nonresponding patients with
advanced fibrosis to consider experimental alternatives in the meantime, provided there is a logical rationale for the treatment
proposed. Some re-treatment strategies still aim to cure the hepatitis C virus infection whereas others focus on limiting
liver damage. The best candidates for the first strategy are patients who had temporary clearance of the virus during previous
treatment and those with hepatitis C virus genotype 2 or 3 infection. Logical candidates for the second strategy are those
who already have advanced fibrosis. It is preferable to pursue further attempts at treatment within the framework of a controlled
trial. Studies with strong rationales include those investigating high-dose peginterferon/ribavirin, long-term peginterferon
suppression, potential immune modulators, and potential inhibitors of liver fibrosis. The rationales are weaker for re-treatment
with a second brand of peginterferon/ ribavirin, daily standard interferon plus ribavirin, and ribavirin monotherapy. 相似文献
6.
Management issues in chronic viral hepatitis: hepatitis C 总被引:6,自引:0,他引:6
Sievert W 《Journal of gastroenterology and hepatology》2002,17(4):415-422
The natural history of chronic hepatitis C virus (HCV) infection and intervention with antiviral therapy are closely linked issues that cause the greatest controversy and concern for the person infected with HCV, as well as for the clinician involved in the assessment and treatment of people with chronic HCV infection. The outstanding challenge of natural history is to identify the person who is likely to develop serious liver disease, and to make that determination early in the course of chronic HCV infection when treatment is likely to be of the greatest benefit. Significant advances in the therapy of chronic HCV infection have occurred over the past decade. A sustained virological response (SVR), defined as undetectable HCV-RNA in blood 6 months after completing antiviral treatment, is the best indicator of a beneficial treatment effect. Relapse, breakthrough or non-response should all be regarded as unsuccessful outcomes of therapy. Interferons are still the mainstay of antiviral therapy for chronic HCV infection. The combination of interferon and ribavirin has improved SVR by decreasing the relapse rate. Treatment responses vary according to host factors such as age and gender, fibrotic severity and to viral factors like genotype and viral load. Patients with genotype 1 HCV and a high viral load require 12 months of treatment to achieve a SVR in approximately 30%, compared to those with genotypes 2 or 3 who achieve a SVR in approximately 65% after 6 months. Patients who relapse after an end-of-treatment response to interferon monotherapy have a good chance of responding to combination interferon and ribavirin given for 6 months, but a longer treatment course should be considered in less optimal cases. At present, the treatment of those with non-response is less clear, but there is interest in more intense forms of interferon therapy, such as induction dosing or pegylated interferon in combination with ribavirin. Clinicians need to be aware of the common side-effects of interferon and ribavirin so that appropriate counseling and testing can be instituted before and during therapy. The combination of pegylated interferon and ribavirin will be the new standard of therapy for hepatitis C and pegylated interferon monotherapy provides quite acceptable efficacy for those patients intolerant of ribavirin. Current data strongly support the concept that SVR in HCV infection (or treatment-induced latency) provides a cure in terms of its beneficial effects on quality of life and sustained amelioration of liver injury. 相似文献
7.
The treatment plan for chronic hepatitis C in special populations varies according to comorbidity and the current evidence on treatment. In patients with hepatitis C virus and HIV coinfection, the results of dual therapy (pegylated interferon plus ribavirin) are poor. In patients with genotype 1 infection, triple therapy (dual therapy plus boceprevir or telaprevir) has doubled the response rate, but protease inhibitors can interact with some antiretroviral drugs and provoke more adverse effects.These disadvantages are avoided by the new, second-generation, direct-acting antiviral agents. In patients who are candidates for liver transplantation or are already liver transplant recipients, the optimal therapeutic option at present is to combine the new antiviral agents, with or without ribavirin and without interferon. The treatment of patients under hemodialysis due to chronic renal disease continues to be dual therapy (often with reduced doses of pegylated interferon and ribavirin), since there is still insufficient information on triple therapy and the new antiviral agents. In mixed cryoglobulinemia, despite the scarcity of experience, triple therapy seems to be superior to dual therapy and may be used as rescue therapy in non-responders to dual therapy. However, a decision must always be made on whether antiviral treatment should be used concomitantly or after immunosuppressive therapy. 相似文献
8.
Shigeru Marubashi Keizo Dono Atsushi Miyamoto Yutaka Takeda Hiroaki Nagano Koji Umeshita Morito Monden 《Journal of hepato-biliary-pancreatic sciences》2006,13(5):382-392
Hepatitis C virus (HCV) infection is the leading cause of endstage liver disease in Western and Asian countries. However, after liver transplantation, HCV recurs in virtually all patients, and estimated HCV-related graft cirrhosis at 5-year follow-up is 30%. Although immunosuppression accounts for a major part of the accelerated progression of HCV in the transplant population, the best immunosuppression for recipients with HCV that could avoid such complication remains unknown at present. Combination therapy of interferon and ribavirin is thought to be the most effective for the treatment or prophylaxis of HCV infection. However, who should be treated, when treatment should be initiated, and with what agent should patients with HCV infection be treated are still unknown. The current data on HCV recurrence in patients who have received either living- or deceased-donor liver transplantation are controversial, but they are, presumably, similar. Thus, to avoid HCV recurrence in living-donor liver transplantation, we have to take approaches similar to those used for patients receiving deceased-donor liver transplantation. Based on reports from major transplant centers around the world, we consider the best strategy for liver transplantation-related HCV infection is steroid-free immunosuppression and preemptive low-dose interferon and ribavirin combination therapy. Here we describe our experience with living-donor liver transplantion for patients with hepatitis C at Osaka University. There is a need for standardizing the treatment for HCV infection. This can only be achieved through collaborative work between various liver transplant centers worldwide. 相似文献
9.
Tien PC;Veterans Affairs Hepatitis C Resource Center Program;National Hepatitis C Program Office 《The American journal of gastroenterology》2005,100(10):2338-2354
Nearly 40% of human immunodeficiency virus- (HIV-) infected veterans on highly active antiretroviral therapy (HAART) in the United States are coinfected with hepatitis C virus (HCV). With the increased survival due to declining opportunistic infections as a result of HAART, HCV-associated liver disease has become a leading cause of death in HIV-infected individuals. HCV infection has been shown to lead to rapid progression of HCV-related liver disease in HIV infection. Results from recent clinical trials in HIV/HCV-coinfected patients show improved response rates using pegylated formulations of interferon plus ribavirin when compared to standard interferon plus ribavirin. However, the treatment of HCV in HIV/HCV-coinfected patients can be complicated by the hepatotoxic and myelosuppressive effects of HIV therapy and HIV infection itself. Prior to initiating HCV therapy, HIV therapy should be optimized by improving immune suppression and avoiding specific antiretroviral drugs that may cause hepatotoxicity and myelosuppression. In the event of treatment-related neutropenia or anemia during HCV therapy, the use of growth factors should be considered to maximize sustained virologic response to HCV therapy. In HIV/HCV-coinfected patients with end-stage liver disease, liver transplantation is being investigated and shows promise as a potential therapeutic option. With the recent advances in the treatment of HCV in HIV/HCV-coinfected individuals, all HIV/HCV-coinfected patients eligible for HCV treatment should be evaluated for HCV combination therapy with careful consideration of their HIV disease. 相似文献
10.
Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in hemophiliacs who received nonvirucidally treated large-pool clotting factor concentrates before 1986. In fact, although many hemophiliacs infected with HCV have a slow progression of liver disease, in a minority of them hepatitis evolves toward end-stage liver disease and hepatocarcinoma. Moreover, a significant percentage of HCV-infected hemophiliacs were also coinfected with human immunodeficiency virus (HIV), which can accelerate the progression of liver disease. Thus, the aim of anti-HCV therapy is to interrupt the chronic infection in order to prevent the progression of hepatitis to cirrhosis, liver decompensation, cancer and, ultimately, death. In this review we present the literature data on anti-HCV treatment in hemophiliacs. Combination therapy with interferon (IFN) and ribavirin has improved the poor results obtained with IFN monotherapy and has become the standard treatment of chronic hepatitis C. Given the positive results obtained with pegylated interferon plus ribavirin in nonhemophiliacs, ongoing trials are evaluating this promising therapy in HCV-chronically infected hemophilic patients; preliminary results show a sustained response rate similar to that in patients without coagulopathy. Finally, based on the encouraging results in coinfected nonhemophiliacs, anti-HCV treatment should also be considered for those HIV-positive hemophiliacs in whom anti-retroviral treatment has stabilized the HIV infection. 相似文献
11.
Hepatitis C affects thousands of children throughout the world. Most children acquire the virus through vertical transmission,
although parenteral routes of acquisition are also common. Hepatitis C progresses slowly, with mild biopsy findings and no
symptoms in most children and in many adults. However, significant liver inflammation and fibrosis can occur in childhood.
Trials of antiviral therapy with interferon and ribavirin have shown these drugs to be effective in almost half of the children
treated. Children tend to tolerate therapy well. Further research on the natural history and treatment of hepatitis C in children
is needed because the infection can have serious long-term consequences, including end-stage liver disease and hepatocellular
carcinoma. 相似文献
12.
Because of shared routes of transmission, coinfection with hepatitis C virus (HCV) or hepatitis B virus (HBV), or both, is common among HIV-infected persons, affecting approximately 15 to 30% and 10 to 15% of patients, respectively. Advances in antiretroviral therapy have improved the life expectancy of patients infected with HIV, and, as a consequence, HCV-related liver disease has emerged as a significant comorbid disease among such patients. Concurrent HIV infection may be associated with higher serum HCV RNA levels, accelerated progression of hepatic fibrosis, increased risk of end-stage liver disease, hepatocellular carcinoma and death among persons coinfected with hepatitis C. Similarly, coinfection with HCV and HBV may lead to more severe liver disease and greater risk of hepatocellular carcinoma (HCC) than does HCV infection alone. Although definitive randomized controlled trials are not yet completed, current guidelines recommend the use of pegylated interferon alfa plus ribavirin for the treatment of chronic HCV in eligible HIV-infected persons. Conversely, the optimal treatment of chronic HCV in persons with chronic HBV infection has not been defined but may include pegylated interferon alfa plus ribavirin, with or without additional antiviral agents, such as lamivudine or adefovir, or both. 相似文献
13.
14.
Opinion statement Multiple factors support treatment of hepatitis C virus (HCV) infection in children. These factors include the anticipated
long duration of infection after early acquisition, relatively good tolerance of antiviral medications, and avoidance of social
stigmatization. Nevertheless, careful selection of appropriate candidates for therapy is important. If a contraindication
to current therapeutic agents is present, treatment should be withheld until this has resolved or until new agents are available.
Children without contraindications to the medications used for HCV should undergo liver biopsy to determine the presence and
degree of fibrosis. In the absence of fibrosis, treatment may be deferred. If any degree of hepatic fibrosis is present, antiviral
therapy for HCV should be considered. At present, in the United States, the only therapy approved for children by the Food
and Drug Administration (FDA) is a combination of interferon (IFN) alfa-2b and ribavirin. No safe therapies have been established
for children younger than 3 years of age. Pegylated interferon in combination with ribavirin may be considered in adolescents
older than 16 years of age who are post-pubertal, or in younger children in the context of clinical trials. Multicenter trials
are currently underway to determine the safety and effectiveness of other forms of therapy for HCV infection in children. 相似文献
15.
J. T. Wilde 《Haemophilia》2004,10(1):1-8
A substantial number of haemophilic patients are infected with both human immunodeficiency virus (HIV) and hepatitis C (HCV). HIV has been shown to accelerate the course of HCV chronic liver disease and there is evidence that HCV infection may worsen the prognosis of HIV. As many HIV infected patients are stable on highly active antiretroviral therapy (HAART) HCV should be actively managed in coinfected individuals. Pegylated interferon (Peg-IFN)/ribavirin combination therapy is the treatment of choice for HCV infection and should be considered in patients with stable HIV on or off HAART with CD4 counts >200 x 10(6)/l. Results of on-going trials of combination therapy in coinfected individuals are awaited. For coinfected patients with end stage liver disease who are stable on HAART liver transplantation should be considered. 相似文献
16.
Of the large number of patients chronically infected with hepatitis C virus (HCV), only about one third have progressive liver disease, and will eventually develop cirrhosis and hepatocellular carcinoma. These are the patients for whom effective antiviral treatment is most needed. Therapy is currently recommended for patients with chronic hepatitis C who have abnormal alanine aminotransferase (ALT) levels, detectable hepatitis C virus ribonucleic acid (HCV RNA) in the blood, and significant necroinflammatory changes and/or fibrosis on liver biopsy. The current gold standard in terms of treatment efficacy is the combination of peginterferon (PEG-IFN) and ribavirin. The overall sustained virological response rate (SVR) with these regimens is 54 to 61% following 48 weeks of therapy. Patients with genotype 1 infection have a 42 to 51% likelihood of response to 48 weeks of therapy. Those with genotypes 2 or 3 infection will respond to 24 weeks of therapy in 78 to 82% of cases. These SVR rates are 5 to 10 percentage points higher in all patient groups than in those obtained with standard doses of interferon (IFN) and ribavirin. Retreatment of nonresponders to standard IFN monotherapy using PEG-IFN and ribavirin has achieved SVR rates of 34 to 40%. Retreatment of patients who relapsed after IFN monotherapy has resulted in an SVR rate of about 60%. A SVR after retreatment of relapsers and nonresponders with PEG-IFN and ribavirin is more likely in patients previously treated with IFN monotherapy, those with HCV genotypes 2 or 3, patients with low viral load (<2 million copies/mL), and individuals who had a significant decrease in HCV RNA levels during the initial treatment. The potential benefits of long-term anti-HCV suppressive therapy in nonresponders are currently under investigation. 相似文献
17.
McHutchison JG 《Journal of gastroenterology and hepatology》2002,17(4):431-441
The vast number of patients with hepatitis C represent a huge medical and economic burden. While 20-30% of these patients progress and develop advanced liver disease, the majority do not. Thus, it is crucial to identify patients suitable for treatment and those who may benefit most from therapy. Anti-viral therapy is recommended for those patients with chronic hepatitis C who also have elevated liver tests, detectable hepatitis C virus ribonucleic acid and significant inflammation and/or fibrosis on liver biopsy. Currently, the most effective initial therapy is the combination of interferon plus ribavirin. The sustained viral response rate (SVR) is 36-41% following a 24- or 48-week course of therapy. In general, patients with the genotype 1 infection should receive 48 weeks of therapy, and those with genotypes 2 or 3 infection only 24 weeks. Viral load estimations are problematic because of normal fluctuations (up to 0.5-10 log), assay variability and lack of a universally accepted standard; thus, viral load testing is not recommended routinely at present. The sustained viral response rate produces improvements in quality of life and liver histology (including reversal of bridging fibrosis and cirrhosis is some), and durable responses lasting 5-11 years in 95-97% of cases. While the optimal dose of ribavirin is currently unknown, available data suggest that higher doses increase efficacy (albeit with a greater degree of anemia). The dose of 800 mg/day may be the most appropriate lower dose for those patients who require dosage modification for anemia or other side-effects. Patients who have relapsed after interferon monotherapy can be successfully retreated with higher doses of interferon for 1 year or the combination of interferon and ribavarin for 24-48 weeks. Preliminary data suggest that patients with an unfavorable profile, including those with genotype 1 infection, should probably be retreated with interferon and ribavirin for 48 rather than 24 weeks. With our current best therapies, the majority of patients still do not achieve the benefits of a sustained response. Re-treatment with interferon and ribavirin may achieve a sustained response in approximately 10-25% of these patients. In the immediate future, once-weekly pegylated interferons will replace standard interferons. Initial data suggest that SVR achieved with these drugs in combination with ribavirin is increased to 54-61%, but dose modifications and side-effects are more frequent. They will thus provide an incremental benefit in terms of efficacy, particularly for genotype 1-infected patients. 相似文献
18.
Rockstroh JK 《Current opinion in infectious diseases》2006,19(1):8-13
PURPOSE OF REVIEW: One third of HIV-infected individuals in Europe and the USA have a hepatitis C coinfection. With the introduction of highly active antiretroviral therapy for treatment of HIV, liver disease caused by chronic hepatitis C virus infection has now become an increasingly important cause of morbidity and mortality among HIV-infected patients. Therefore, treatment strategies for management of hepatitis C coinfection in HIV-infected individuals are urgently needed. RECENT FINDINGS: With the introduction of pegylated interferon/ribavirin combination therapy significantly improved treatment options for HIV/hepatitis C virus-coinfected patients have become available, leading to sustained virological response rates of over 40%. Increasing knowledge on the management of adverse events under hepatitis C therapy and optimized selection of antiretrovirals in HIV/hepatitis C virus-coinfected patients has helped to reduce complications and improve overall treatment outcome. SUMMARY: Treatment with pegylated interferon plus ribavirin is safe and effective in HIV/hepatitis C virus-coinfected patients. Longer treatment durations of 48 weeks are recommended for genotype 2 or 3. Positive predictive factors for sustained response are hepatitis C virus genotype 2 or 3 and early treatment response. 相似文献
19.
Up to 25% of patients with chronic hepatitis C have persistently normal serum alanine aminotransferase (ALT) levels. Reports
from some studies indicate that patients with normal ALT levels are more likely to be female and nondrinkers. Patients with
persistently normal aminotransferase levels often have mild disease on liver biopsy with little or no fibrosis, but a small
number of patients may have substantial fibrosis or cirrhosis. Treatment with interferon monotherapy has been disappointing.
Combination therapy with interferon and ribavirin is controversial, but early clinical results have shown good response rates.
Currently, therapy for chronic HCV patients with normal ALT levels should be based upon results from liver biopsy and preferably
be done in the context of a clinical trial. 相似文献
20.
Takuro Igawa Soichiro Fushimi Ryuichi Matsuo Fusao Ikeda Kazuhiro Nouso Tadashi Yoshino Harushige Nakatsukasa 《Clinical journal of gastroenterology》2014,7(5):465-470
A second-generation direct-acting antiviral agent, simeprevir, now provides a new treatment option for hepatitis C virus (HCV) infection with good safety profile in combination with pegylated interferon and ribavirin. We herein report a rare case of severe liver injury under simeprevir plus pegylated interferon/ribavirin therapy. We initiated this therapy in a 65-year-old male with treatment-naïve genotype 1b HCV. On day 28, the patient’s HCV-RNA was successfully eliminated, and his liver function was fully restored. However, on day 49, the serum alanine aminotransferase level was elevated at 700 IU/L. The HCV-RNA titer was still undetectable and the involvement of other possible viruses was negligible. A liver biopsy performed on day 60 showed an acute hepatitis pattern. The discontinuation of therapy alone successfully improved his liver damage on day 84. No other treatments such as steroids were required. According to the diagnostic criteria for drug-induced liver injury in Japan (DDW-J2004), the liver injury observed in this case can be associated with the administration of simeprevir plus pegylated interferon/ribavirin therapy. In conclusion, simeprevir plus pegylated interferon/ribavirin should be used with caution, as these agents may cause unreported serious adverse events including severe liver injury, despite their clinical safety profile. 相似文献